Janssen Sciences Ireland Uc

Medivir Ab

Janssen R&d Ireland

Tibotec Pharmaceuticals Ltd.

Janssen Products, LP

Tibotec Bvba

Tibotec Pharmaceuticals Ltd. Co

Janssen Sciences Ireland Unlimited Company

Medivir Aktiebolag

Lili Hu

Pierre Jean-Marie Bernard Raboisson

Scott D Kuduk

Abdellah Tahri

Sandrine Marie Helene Vendeville

Tim Hugo Maria Jonckers

Samuël Dominique Demin

Ludwig Paul Cooymans

Herman Augustinus De Kock

Dominique Louis Nestor Ghislain Surleraux

Karl Magnus Nilsson

Per-Ola Mikael Johansson

Vladimir Kirillovich Ivanov

Mikael Pelcman

Koen Vandyck

Wim Van De Vreken

Steven Maurice Paula Van Hoof

David Craig McGowan

Anna Karin Gertrud Linea Belfrage

Pierre Jean-Marie Raboisson

Stefaan Julien Last

Bart Rudolf Romanie Kesteleyn

Kenneth Simmen

Bengt Bertil Samuelsson

Åsa Annica Kristina Rosenquist

Anna Karin Gertrud Linnea Belfrage

Piet Tom Bert Paul Wigerinck

Hans Kristian Wallberg

Wim Gaston Verschueren

Serge Maria Aloysius Pieters

Pia Kahnberg

Geerwin Yvonne Paul Haché

Sandrine Vendeville

Zhanling Cheng

Geert Rombouts

David Craig Mc Gowan

Samuel Dominique Demin

Jan Martin Berke

Origéne Nyanguile

Björn Olof Classon

Sandrine Céline Grosse

Lourdes Salvador Odén

Gang Deng

Abdellah Tahari

Karin Charlotta Lindquist

Horst Jürgen Wähling

Mats Stefan Lindström

Carolina Martinez Lamenca

Ismet Dorange

Anna Karin Belfrage

Sven Crister Sahlberg

Steven Maurice Van Hoof

Origène Nyanguile

Michael Pelcman

Morgan Charles R Lecomte

Yvan Simonnet

Vladimir Ivanov

Anna Karin Gertrud L c/o Medivir Ab Belfrage

Bengt Bertil c/o Medivir Ab Samuelsson

Michael c/o Medivir Ab Pelcman

Vladimir c/o Medivir Ab Ivanov

Åsa Annica Kristina c/o Medivir Ab Rosenquist

Karl Magnus c/o Medivir Ab Nilsson

Per-Ola Mikael c/o Medivir Ab Johansson

Pia Cecilia Kahnberg

ÅSa Annica Kristina Rosenquist

Horst Jürgen WÄHLING

Geerwin Yvonne Paul HachÉ

Sandrine Marie Vendeville

Tim Hugo Jonckers

Kenneth Alan Simmen

Yimin Jiang

Yanping Xu

Inhibitors of HBV replication of Formula (I-A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Rto R, and Rto Rhave the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B

The invention concerns novel substituted tricyclic pyrazolo pyrimidine compounds of formula (I-a) or (I-b) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection. 

Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)

The invention concerns novel substituted bicyclic pyrazolo pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection. 

Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)

Indoles having inhibitory activity on RSV replication and having the formula I the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof; compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

Indoles as respiratory syncytial virus antiviral agents

Azaindoles having inhibitory activity on RSV replication and having the formula I compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

Azaindoles as respiratory syncytial virus antiviral agents

A compound satisfying formula I, a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof; compositions contain these compounds as active ingredient and processes for preparing these compounds and compositions.

Azabenzimidazoles as respiratory syncytial virus antiviral agents

Inhibitors of HCV replication of formula (I) 

Macrocyclic inhibitors of hepatitis C virus

The present invention is concerned with novel 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof,wherein R, R, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents

The invention concerns novel substituted spiro urea azetidinyl or piperidinyl compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection. 

Spiro urea compounds as RSV antiviral compounds

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein

Inhibitors of RSV replication of formula RI including stereochemically isomeric forms, and salts or solvates thereof, wherein R, W, Q, V, Z p, s, and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.

RSV antiviral compounds

Inhibitors of HCV replication of formula (I) and the salts and stereoisomers thereof, wherein

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond;

The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof,  The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

Macrocyclic indoles as hepatitis C virus inhibitors

Growing community of inventors

Mechelen, Belgium

Lili Hu